ClinicalTrials.gg

Hyperlipidemias clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 862 studies for Hyperlipidemias across more than 10 countries. 109 are recruiting or about to start. 363 of them are mainly about Hyperlipidemias (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16. Counting its 7 narrower conditions too, such as Hypercholesterolemia: 2,413 studies, 274 open.

ClinicalTrials.gov finds 2,430 studies for Hyperlipidemias. How that becomes 861 here

This page counts the studies the registry files under Hyperlipidemias, and those it files under no condition that list Hyperlipidemiasthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 2,430Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −1,479Filed under a narrower condition, counted on its own pageHypercholesterolemia 993 · Hypertriglyceridemia 256 · Hyperlipoproteinemia Type II 155 · Homozygous Familial Hypercholesterolemia 38 · Hyperlipoproteinemias 16 · Hyperlipoproteinemia Type I 13 · 1 more
  3. −5List Hyperlipidemias as a condition, but the registry did not file them under itMost often written as “Hyperlipemia, Carbohydrate Inducible” (1), “Carbohydrate Inducible Hyperlipemia” (1), and “Hyperlipidemia in Children” (1). The registry filed them under other conditions only, most often Hyperlipoproteinemia Type IV (2) and Hyperlipoproteinemia Type V (2).
  4. −85Match it another way28 name it in the title, 5 in a keyword, and 52 by a synonym or other text the search reads.
  5. 861The count on this page15 of them list Hyperlipidemias in their own words; the registry filed them under no condition.

Status

Completed
597
Status unknown
82
Recruiting
67
Not yet recruiting
33
Terminated
33
Active, not recruiting
23

Phase

Phase 3
171
Phase 1
117
Phase 2
113
Phase 4
73
Early Phase 1
9

Where

United States
338
Canada
94
China
94
Korea, Republic of
79
Taiwan
40
United Kingdom
40

Who develops what

Add Hyperlipidemias to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 34 programs from 19 companies, 21 with this as their studies’ main aim; 9 with a live phase 3 study; 6 primary completions in the next 12 months. Compare Yuhan, Jiangsu HengRui Medicine and AstraZeneca here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
AtorvastatinEarlier only
Evidence
  • NCT02977065 · Chong Kun Dang Pharmaceutical · Phase 2 · comparator · “Atorvastatin 20mg” · registered Nov 2016
  • NCT02662569 · Amgen · Phase 3 · background · “Atorvastatin” · registered Jan 2016
  • NCT02659397 · Esperion Therapeutics, Inc. · Phase 2 · background · “Atorvastatin” · registered Jan 2016
  • NCT02227784 · Eli Lilly and Company · Phase 3 · background · “Atorvastatin” · registered Aug 2014
  • NCT02135029 · Pfizer · Phase 3 · comparator · “Atorvastatin” · registered May 2014
Viatris Inc.16% of its industry studiesUS: off-patent, 23 generics marketed00 studies
rosuvastatinEarlier only
Evidence
  • NCT02977065 · Chong Kun Dang Pharmaceutical · Phase 2 · comparator · “Rosuvastatin 10 mg” · registered Nov 2016
  • NCT02280590 · dong a st · Phase 4 · comparator · “Rosuvastatin(Crestor®)” · registered Oct 2014
  • NCT01914432 · Yuhan Corporation · Phase 3 · comparator · “Rosuvastatin” · registered Jul 2013
  • NCT00249912 · Takeda · Phase 3 · comparator · “Rosuvastatin” · registered Nov 2005
AstraZeneca38% of its industry studiesUS: off-patent, 17 generics marketed00 studies
EzetimibeEarlier only
Evidence
  • NCT03337308 · Esperion Therapeutics, Inc. · Phase 3 · comparator · “Ezetimibe” · registered Nov 2017
  • NCT02227784 · Eli Lilly and Company · Phase 3 · comparator · “Ezetimibe” · registered Aug 2014
  • NCT01984424 · Amgen · Phase 3 · comparator · “Ezetimibe” · registered Nov 2013
  • NCT01763827 · Amgen · Phase 3 · comparator · “Ezetimibe” · registered Jan 2013
  • NCT01763866 · Amgen · Phase 3 · comparator · “Ezetimibe” · registered Jan 2013
Organon & Co.59% of its industry studiesUS: off-patent, 14 generics marketed00 studies

4 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
inclisiranApproved: US 2021 · EU 2020☆ Track5 live phase-3 studies: NCT05030428, NCT05739383, NCT07102628Novartis
bempedoic acidApproved: US 2020 · EU 2020☆ Track1 live phase-3 study: NCT07623915cspc pharmaceutical group
SHR-1918☆ Track1 live phase-3 study: NCT07230730Jiangsu HengRui Medicine Co., Ltd.
obicetrapib☆ Track2 live phase-3 studies: NCT07219602, NCT06305559NewAmsterdam Pharma
enlicitide☆ Track1 live phase-3 study: NCT07216482Merck & Co., Inc

The 5 in phase 3 with the nearest primary completion, of 34 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (6)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 11 Feb 2027 est.inclisiran · Novartis · Phase 3 registry mapping onlyNCT07102628 Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes — primary endpoint: Percent change in LDL-C · 300 enrolled
  • 26 Apr 2027 est.DII235 · Novartis · Phase 2 registry mapping onlyNCT07235046 A Study of DII235 in Adults With Elevated Lipoprotein(a) — primary endpoint: Time averaged percentage change from baseline between Day 60 and Day 180 · 234 enrolled
  • 10 May 2027 est.inclisiran · Novartis · Phase 3 registry mapping onlyNCT05030428 Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease — primary endpoint: Time to First Occurrence of 3P-MACE (3-Point Major Adverse Cardiovascular Events) · 17,004 enrolled

3 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Hyperlipidemias studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Statins 3 open · PCSK9 inhibitors 24 · Angiotensin receptor blockers (ARBs) 12 · Calcium channel blockers 7

Coming up

42studies finish main data collection within a year8 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 67 Hyperlipidemias studies recruiting now, 27 (40%) set no upper age limit and 32 (48%) stop at 75 or younger. 8 (12%) take children under 18. 2 (3%) are for women only and 2 (3%) for men only; 16 (24%) take healthy volunteers.

Recruiting studies that take each age, of 67
AgeWomenMen
105 (7%)5 (7%)
1843 (64%)44 (66%)
3052 (78%)52 (78%)
4057 (85%)57 (85%)
5058 (87%)58 (87%)
6552 (78%)52 (78%)
7541 (61%)41 (61%)
8528 (42%)29 (43%)

Across all 862 studies, recruiting or not: 47% stop at 75 or younger and 29% at 65; 6% take children; 3% are for women only and 7% for men only; 36% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Hyperlipidemias studies take

Of 57 phase 3 interventional studies under Hyperlipidemias, half reached primary completion within 18 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 13 mo1–10 · 54 studies3 mo1–10 · 47 studies—
Phase 216 mo10–27 · 30 studies——
Phase 318 mo11–32 · 57 studies18 mo10–26 · 51 studies—
Phase 428 mo16–44 · 18 studies——
Interventional, no phase15 mo7–31 · 171 studies—16 mo7–31 · 166 studies
Observational28 mo11–68 · 35 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 862. Browse all 862 → or search them.